Psoriasis is caused by a complex interplay between the immune system, psoriasis-associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last 2 decades, research has unequivocally shown that psoriasis represents a bona fide T cell-mediated disease primarily driven by pathogenic T cells that produce high levels of IL-17 in response to IL-23. The discovery of the central role for the IL-23/type 17 T-cell axis in the development of psoriasis has led to a major paradigm shift in the pathogenic model for this condition. The activation and upregulation of IL-17 in prepsoriatic skin produces a ''feed forward'' inflammatory response in keratinocytes that is self-amplifying and drives the development of mature psoriatic plaques by inducing epidermal hyperplasia, epidermal cell proliferation, and recruitment of leukocyte subsets into the skin. Clinical trial data for mAbs against IL-17 signaling (secukinumab, ixekizumab, and brodalumab) and newer IL-23p19 antagonists (tildrakizumab, guselkumab, and risankizumab) underscore the central role of these cytokines as predominant drivers of psoriatic disease. Currently, we are witnessing a translational revolution in the treatment and management of psoriasis. Emerging bispecific antibodies offer the potential for even better disease control, whereas small-molecule drugs offer future alternatives to the use of biologics and less costly long-term disease management. (J Allergy Clin Immunol 2017;140:645-53.) 
Psoriasis vulgaris is a common chronic inflammatory skin condition that affects 2% to 3% of persons in the United States. 1 Plaque psoriasis, the most common disease variant, which is seen in approximately 85% of cases, commonly manifests as erythematous plaques with thick scaling on the extensor surfaces, trunk, and scalp. 2 The severity of psoriasis ranges from mild disease with a limited number of localized inflammatory skin lesions to more severe disease involving widespread plaques that cover more than 10% of the body surface area. Approximately one third of patients with chronic disease go on to develop psoriatic arthritis, an inflammatory arthritis characterized by asymmetric oligoarthritis, nail disease, enthesitis, and/or dactylitis. 3 Other less common psoriasis subtypes include erythrodermic, pustular, guttate, inverse, and palmoplantar psoriasis.
The economic burden associated with the care of patients affected by psoriasis is significant and accounts for billions of dollars spent annually in the United States alone. 4 As is seen with other chronic medical conditions, patients with psoriasis report a tremendous psychosocial burden and experience a significant reduction in their physical activity, cognitive function, and quality of life. 5 The cause of psoriasis is complex and driven primarily by an aberrant immune response in the skin that is modified by genetic susceptibility and various environmental stimuli (eg, skin trauma, infections, and medications). The detrimental inflammatory events associated with psoriatic disease are not restricted to the skin and account for an increasing number of comorbid conditions, including cardiometabolic disease, stroke, metabolic syndrome (obesity, hypertension, dyslipidemia, and diabetes), chronic kidney disease, gastrointestinal disease, mood disorders, and malignancy. 6 These disease-associated comorbidities account in part for the increased mortality seen in patients with psoriasis and have substantial implications on disease management. In the last decade, research discoveries have significantly expanded our understanding of the pathophysiology of psoriasis and have directly led to the development of highly effective targeted psoriasis therapies, such as those against IL-17 and IL-23. The superiority of these novel agents compared with traditional systemic agents underscores the central importance of the IL-23/type 17 T (T17) cell axis in psoriatic disease.
In this review we will discuss recent updates in the working model of psoriasis pathogenesis, outline the effects of IL-23/ T17 cell axis signaling on skin biology, and provide an overview of the development and clinical testing of IL-17 and IL-23 inhibitors for the treatment of psoriasis and related chronic inflammatory skin conditions.
PSORIASIS AS A T CELL-MEDIATED AUTOIMMUNE CONDITION
The requirement of the immune response for the development of psoriasis was suggested by early observations that characteristic skin lesions contained increased numbers of inflammatory cellular infiltrates. 9, 10 Additionally, patients with psoriasis undergoing bone marrow transplantations 11 or treatment with immunosuppressive agents, such as cyclosporine 12, 13 and methotrexate, 14 experienced dramatic improvements in their inflammatory skin lesions. Subsequent experiments found that the inflammatory infiltrate in lesional skin was largely composed of CD4
1 and CD8 1 T cells. 9, 15 However, selective inhibition of activated T cells in patients through a novel fusion protein made of human IL-2 and diphtheria toxin fragments (DAB 389 IL-2) provided definitive proof for the pathogenic role of T cells in psoriasis. 16 Multiple proof-of-concept clinical trials targeting the activated immune response in psoriatic skin with abatacept (fusion protein of the Fc region of the immunoglobulin IgG 1 and the extracellular domain of cytotoxic T lymphocyte-associated antigen 4), 17 alefacept (CD2-directed lymphocyte function-associated antigen 3/Fc fusion protein), 18 and efalizumab (a recombinant humanized mAb against CD11a) 19 also proved effective in reversing the psoriasis phenotype and further established the role of the T lymphocyte in this condition. Such studies laid the groundwork for subsequent clinical trials aimed at other aspects of the immune response and the specific cell-signaling pathways outlined in greater detail below.
The mounting evidence for the pathogenic role of T lymphocytes in patients with psoriasis and the observation that disease was more frequently observed in familial clusters 20, 21 led many to conclude that psoriasis was an autoimmune condition with a strong genetic basis. Early genome-wide association studies in the 1980s revealed multiple psoriasis-associated susceptibility loci, the strongest of which was the human leukocyte antigen locus (HLA-C*06:02).
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Since that time, 63 unique susceptibility loci have been identified in patients of European descent with psoriasis, 23 although these loci only explain approximately 50% of the heritability of psoriasis. Additionally, the absence of expanded T-cell receptor (TCR) clones 24 and the failure to identify any consistent exogenous or self-antigens caused others to question the autoimmune basis of psoriasis. However, the recent identification of 3 psoriasis autoantigens and their potential role in the pathogenesis of this condition has renewed interest in the autoimmune hypothesis. 25 
Psoriasis autoantigens
In a recent study of 56 patients, Lande et al 26 found that peripheral blood in 75% of patients with moderate-to-severe psoriasis contained autoreactive CD4 1 or CD8 1 T cells against LL-37/ cathelicidin, a cationic antimicrobial peptide (AMP) produced by keratinocytes and other immune cells (eg, neutrophils) in response to bacterial/viral infections 27, 28 or skin trauma. 29 The cytokine profile of these autoreactive T cells revealed increased levels of skin-homing receptors (eg, cutaneous lymphocyte antigen, CCR6, and CCR10) and a strong IFN-g and IL-17 phenotype consistent with previous studies examining the T-cell CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA-4): An immunoglobulin family transmembrane protein expressed on peripheral T cells after activation. CTLA-4 contains immune tyrosine inhibitory motifs. CTLA-4 inhibits T cells by competing for ligands with CD28 and by associating with Src-homology domain 2-containing protein tyrosine phosphatase 2 and protein phosphatase 2 to affect proximal TCR signaling. CTLA-4 deficiency, an autosomal dominant primary immunodeficiency, results in impaired function of regulatory T cells, leading to autoimmune cytopenias, enteropathy, interstitial lung disease, recurrent infections, and extralymphoid lymphocytic infiltration.
DACTYLITIS:
Inflammation of an entire digit. When accompanied by soft-tissue swelling, the term ''sausage digit'' is often applied.
ENTHESITIS:
Inflammation of the enthesis, the site of attachment of a tendon, ligament, or joint capsule onto bone or cartilage. The editors wish to acknowledge Daniel Searing, MD, for preparing this glossary.
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populations found in psoriatic skin. 30 Importantly, the authors also showed that LL-37 expression is upregulated in psoriatic plaques, correlates with disease activity, and results in direct activation of plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs) by forming a complex with nucleic acids (DNA and RNA) released after skin trauma. 29, 31 These multimeric LL-37-nucleic acid complexes are protected from enzymatic degradation and enter dendritic cells (DCs) by way of specific Toll-like receptors. LL-37-mediated activation of DCs in the skin results in overproduction of type I interferons (IFN-a and IFN-b) by pDCs and increased amounts of TNF and IL-6 by mDCs. 31, 32 A similar mechanism for pDC activation has also been described for human b-defensin (hBD) 2, hBD3, and lysozyme. 33 This mechanism wherein 1 or more AMPs are released by keratinocytes and other immune cells in response to skin damage or external stimuli provides a framework for how these proteins can break tolerance and promote autoimmunity in patients with psoriasis.
In 2015, a second potential psoriasis autoantigen, a disintegrinlike and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5), was described by Arakawa et al.
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ADAMTSL5 (also known as ADAMTS-like protein 5) is a secreted zinc metalloprotease-related protein 35 thought to regulate components of the extracellular matrix. 36 Using a reconstituted TCR of an epidermal CD8
1 T-cell clone collected from a HLA-C*06:02-positive patient with psoriasis, Arakawa et al 34 observed that HLA-C*06:02-restricted melanocytes resulted in TCR activation. The authors also observed a close spatial association between CD8
1 T cells and HLA-C*06:02-restricted melanocytes, which were found to express increased amounts of ADAMTSL5. These findings suggest that the increased number of ADAMTSL5-expressing melanocytes in HLA-C*06:02-positive patients can serve as direct autoimmune targets for pathogenic T17 cell populations in psoriatic skin. This hypothesis is further supported by the finding that ADAMTSL5 stimulation of PBMCs isolated from patients with psoriasis, regardless of HLA-C*06:02 status, resulted in increased expression of IL-17A and IFN-g in approximately two thirds of patients compared with healthy control subjects. 34 Importantly, recent results from our laboratory suggest that the possibility of ADAMTSL5 antigen presentation and the subsequent activation of IL-17-producing T cells in psoriatic skin might involve other immune cell populations, such as keratinocytes and DCs. 37, 38 Most recently, phospholipase A 2 group IVD (PLA2G4D) was reported as a possible psoriasis autoantigen. 39 Unlike related phospholipase enzymes, PLA2G4D is a novel protein found to be upregulated in psoriatic plaques. 40, 41 Its expression is increased in psoriatic keratinocytes and mast cells and results in the generation of nonpeptide neolipid antigens presented on CD1a-expressing DCs for recognition by autoreactive T cells. 39 These autoreactive T cells were also found to be enriched in the peripheral blood of patients with psoriasis and produced high amounts of IFN-g and IL-17A when coincubated with PLA2G4D-and CD1a-expressing cells. Unexpectedly, PLA2G4D activity was shown to localize with tryptase in mast cells, and neolipid antigens could be transferred to neighboring antigen-presenting cells through mast cell-derived exosomes in a clathrin-dependent manner. 39 Theses findings provide convincing evidence for the immunogenicity of nonprotein lipid antigens in psoriasis in addition to traditional peptide antigens, such as LL-37 or ADAMTSL5.
In summary, the requirement for T cells in the development of psoriasis is undeniable. However, the precise mechanisms by which environmental factors and known susceptibility loci trigger the onset of psoriasis is not well understood. The link between psoriasis-related autoreactive T cells and distinct HLA-restricted autoantigens provides a possible mechanism for disease onset in predisposed subjects. It might also help explain why increased numbers of CD1a 1 T cells found in the peripheral blood of patients with psoriasis are also positive for cutaneous lymphocyte antigen. Unfortunately, little is known about the exact immune events leading to the loss of immune tolerance in subjects susceptible to psoriasis. It is essential that future studies explore these molecular mechanisms and carefully characterize the expression profiles of potential autoantigens in all cell types found in the skin and blood of patients with psoriasis, 38 as well as their relationship to major psoriasis susceptibility loci.
THE PIVOTAL ROLE OF IL-17 IN UPDATED DISEASE MODELS OF PSORIASIS
For many years, psoriasis was primarily characterized as a T H 1-driven disease based on increased production of IFN-g by CD4
1 T cells found in psoriatic tissues compared with low production of cytokines that define the T H 2 T-cell subset (ie, IL-4, IL-5, and IL-13). However, with the characterization of a novel T H 17 cell subset discovered in the experimental autoimmune encephalomyelitis mouse model commonly used to study multiple sclerosis, 42 the field of dermatology research experienced a major paradigm shift in the way chronic inflammatory diseases of the skin were defined. This murine T H 17 subset was characterized by its production of IL-17 and IL-22 by CD4 1 T cells. Ultimately, it was discovered that IL-17 blockade results in complete reversal of the molecular and clinical disease features seen in the majority of patients with psoriasis, thus placing IL-17 and IL-17-producing T cells at the center of the current model for psoriatic disease (Fig 1) . Of note, most IL-22 is synthesized by a distinct T H 22 T-cell subset in human subjects.
A number of cell types found in the skin make IL-17, including CD4 1 T cells (T H 17), CD8 1 T cells (T C 17), innate lymphoid cells, and gd T cells. [43] [44] [45] IL-17 production in these cells is driven by IL-23, which is principally made by dermal DCs. After presentation of specific psoriasis autoantigens and/or certain environmental stimuli (eg, trauma or infection) in prepsoriatic skin, T17 producing cells in the skin make substantial amounts of IL-17 (IL-17A/IL-17F), as well as TNF, IL-26, and IL-29 (IFN-l1) . 46 Together, these cytokine signals create a ''feed forward'' inflammatory response in keratinocytes by activating CCAAT enhancer-binding protein (C/EBP) b or d, signal transducer and activator of transcription (STAT) 1, and nuclear factor kB, which lead to the upregulation of a number of keratinocyte-derived inflammatory products (Fig 2) . This feed forward response is self-amplifying and, ultimately, drives the development of mature psoriatic plaques by inducing epidermal hyperplasia, regulating epidermal cell proliferation, and recruiting leukocyte subsets into the skin. IL-17 also acts synergistically with TNF to potentiate IL-17-induced transcription of several proinflammatory genes (eg, TNF, IL-1b, IL-6, and IL-8), [47] [48] [49] [50] which activate mDCs and promote the differentiation of T17 cells in the skin and draining lymph nodes. 32, 51 Epidermal hyperplasia, a hallmark of psoriatic plaques, is associated with STAT3 activation and indirectly regulated by J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 3 IL-17 through induction of IL-19 and/or IL-36 by keratinocytes. 46 The increased proliferation of epidermal keratinocytes is likely further potentiated by IL-22 and possibly IL-20 because both of these cytokines are also activators of STAT3. 52, 53 This marked thickening of the rapidly proliferating epidermis is accompanied by retention of the keratinocyte nucleus (parakeratosis), as well as upregulation of IL-17-induced transcription factors (eg, C/EBPb or C/EBPd) and keratinocyte-derived gene products, such as S100A7/8/9, hBD2, lipocalin-2, and CCL20. 54 These keratinocyte-derived proteins accumulate and are noticeably increased in the upper spinous and granular layers of the epidermis of psoriatic lesions, paralleling higher expression of C/EBPb or C/EBPd in more well-differentiated keratinocytes (Fig 2) . High expression of S100A7 and AMPs creates a skin barrier highly resistant to skin infections, unlike atopic dermatitis, which is commonly associated with bacterial and viral infections.
Another primary function of IL-17 in psoriasis is the recruitment of leukocyte subsets into inflamed psoriatic plaques. IL-17 induces keratinocytes to synthesize and release CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8 (ie, IL-8), which lead to neutrophil and macrophage recruitment. Infiltrating neutrophils form collections in the upper layers of the epidermis and stratum corneum called Munro microabscesses. IL-17A, IL-22, and TNF also stimulate CCL20 expression in keratinocytes, which in turn attract CCR6
1 cells (including mDCs and T17 cells) and sustain the inflammatory response through a positive chemotactic feedback loop. 55 The interferon-like cytokines (IL-26 and IL-29) secreted by T17 cells also activate STAT1 in keratinocytes, leading to expression of CXCL9, CXCL10, and CXCL11, which attract T H 1 cells into psoriatic skin and sensitize keratinocytes to keratinocyte-derived proinflammatory signals. 56, 57 Psoriatic keratinocytes also synthesize other growth factors, which affect connective tissue cells in the dermis; platelet-derived growth factor, angiopoietin-2, and vascular endothelial growth factor likely drive angiogenesis, which account for erythematous skin lesions. 58 
TNF ANTAGONISTS
TNF is a potent proinflammatory cytokine made by a variety of immune cells found in the skin, including T cells, keratinocytes, DCs, and macrophages. Its upregulation in the skin of patients with psoriasis has been well characterized. 59, 60 The clinical efficacy of multiple TNF antagonists (eg, adalimumab, etanercept, and infliximab) underscore the importance of this cytokine in the promotion and maintenance of psoriatic skin lesions, although the percentage of patients experiencing dramatic improvement in their skin lesions is significantly lower than those seen with novel IL-17 and IL-23 antagonists.
The efficacy of TNF antagonists in patients with psoriasis is likely related to their indirect effects on IL-23/T17 cell signaling. One of the primary effects of TNF in psoriasis is its regulation of IL-23. In response to some triggering event in the skin (eg, trauma or infection), TNF released by pDCs results in increased production of IL-23 from mDCs. mDCs that produce TNF and inducible nitric oxide synthase, also known as TIP-DCs, are increased in psoriasis plaques and are the major source of IL-23 in psoriatic skin. 30, 61 The increased production of IL-23 by mDCs is the primary signal driving activation of T17 cells in psoriasis plaques, as well as the broad immune activation observed in proliferating keratinocytes (Fig 1) . In addition to its upstream induction of IL-23, TNF also acts synergistically with IL-17 to increase and sustain the upregulation of many psoriasis-related proinflammatory genes made by epidermal keratinocytes. In this way the clinical efficacy of TNF antagonists might be due in large part to their indirect inhibition of the IL-23/T17 cell signaling pathway in the skin. and AMPs (eg, hBD2, S100A7, and LL-37), epidermal recruitment of leukocyte subsets (eg, neutrophils and mDCs) through increased production of keratinocyte-derived chemokines, and transcription of multiple proinflammatory genes (eg, IL-1b, IL-6, and IL-8) that act synergistically with TNF to sustain the inflammatory events in psoriatic skin.
RECENTLY APPROVED AND NOVEL THERAPEUTIC AGENTS FOR PSORIASIS
The discovery of the T17 cell population and elucidation of the broad effects of the IL-23/T17 cell signaling axis on keratinocytes and infiltrating immune cells in the skin has largely shaped the current disease model of psoriasis. Therefore psoriatic disease is best understood as a patterned response to chronic activation of the IL-23/T17 cell pathway. For this reason, current therapeutic strategies are now focused on the development of novel agents that disrupt IL-23 or IL-17 cytokine signaling. In the subsequent sections of this review, we will discuss the testing and development of several approved IL-17 antagonists, as well as several IL-23 inhibitors currently in development and clinical testing.
IL-17 inhibition
To date, 3 IL-17 pathway antagonists have been approved for the treatment of psoriatic disease: secukinumab, ixekizumab, and brodalumab. Phase III clinical trials have demonstrated the high efficacy, tolerability, and safety of these inhibitors. The commercialization of the IL-17 antagonists has transformed the way patients with psoriatic disease are being treated in the clinic.
Secukinumab, a fully human mAb against IL-17A, was the first inhibitor of its kind approved for the treatment of psoriatic disease. Secukinumab was approved in January 2015 for the treatment of moderate-to-severe psoriasis. The following year, it received FDA approval for the treatment of psoriatic arthritis and ankylosing spondylitis. Phase III clinical trials (ie, the ERASURE/ FIXTURE 62 and CLEAR 63, 64 trials) have demonstrated that more than 75% of patients with plaque psoriasis treated with secukinumab achieved a 75% improvement in their Psoriasis Area and Severity Index (PASI75) response, with a significant portion also achieving PASI90 and PASI100 responses. In the CLEAR trial 64 nearly 80% of treated patients achieved a PASI90 response at week 16 compared with only 58% in a comparison cohort treated with ustekinumab (a selective antagonist of the p40 subunit shared by IL-12 and IL-23). In clinical trials evaluating patients with psoriatic arthritis treated with secukinumab (FUTURE-1 and FUTURE-2), 65, 66 just over half of all patients achieved a 20% improvement in the American College of Rheumatology criteria (ACR20) for tender or swollen joints. Similar to secukinumab, ixekizumab is a humanized IgG 4 mAb directed against IL-17A. In March 2016, ixekizumab was approved for the treatment of moderate-to-severe plaque psoriasis. Three double-blind, placebo-controlled, phase III studies using ixekizumab for plaque psoriasis (UNCOVER-1, UNCOVER-2, and UNCOVER-3) 67,68 underscore the high efficacy associated with IL-17 blockade in patients with psoriatic disease. Around 80% to 90% of patients in the UNCOVER trials achieved a PASI75 response compared with fewer than 10% and 40% to 50% in the placebo and etanercept arms, respectively. The percentage of patients with psoriatic arthritis achieving an ACR20 response after treatment with ixekizumab (SPIRIT-P1) is comparable with those from the FUTURE trials for secukinumab 69 ; the SPIRIT-P2 trial is ongoing and results have not yet been released (ClinicalTrials.gov registration no. NCT02349295). The future approval of ixekizumab for the treatment of psoriatic arthritis is probable based on the favorable results of the SPIRIT-P1 study.
Brodalumab, a human mAb that inhibits the IL-17 receptor, was approved for the treatment of moderate-to-severe plaque psoriasis in February 2017. Three randomized, double-blind, placebo-controlled phase III studies evaluated the efficacy of brodalumab for the treatment of moderate-to-severe plaque psoriasis: AMAGINE-1, AMAGINE-2, and AMAGINE-3.
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More than 80% of patients with psoriasis treated with brodalumab achieved a PASI75 response at the primary end points of the AMAGINE trials, and brodalumab was shown to be superior to both placebo and ustekinumab. Two clinical trials for the evaluation of brodalumab in the treatment of psoriatic arthritis (AMVISION-1 and AMVISION-2) have been performed, but study results are not available publicly (ClinicalTrials.gov registration nos. NCT02029495 and NCT02024646).
The available safety information for secukinumab, ixekizumab, and brodalumab is reassuring. Common adverse side effects noted in clinical trials include upper respiratory tract infections, headache, nasopharyngitis, mild neutropenia, Candida albicans mucocutaneous infections, and diarrhea. The association of IL-17 blockade with Candida infections likely reflects the normal role for this cytokine in the innate immune response against this organism; therefore its absence renders the skin susceptible to overgrowth in the skin and mucosal tissues, as observed in patients with inborn errors in IL-17. 72 Less common side effects reported were arthralgias, fatigue, inflammatory bowel disease, and injection-site reactions. The potential association with IL-17 inhibition and gastrointestinal disorders is of interest given that secukinumab and brodalumab testing for the treatment of inflammatory bowel disease caused worsening of symptoms in some patients. Lastly, 4 suicides were reported in the AMAGINE trials for brodalumab, raising some concerns regarding the safety of this agent, although no causal relationship was ever demonstrated. Nevertheless, the Risk Evaluation and Mitigation Strategy (REMS) was instituted to provide required surveillance for suicide and suicidal ideation in patients treated with brodalumab.
IL-23 inhibition
As a ''master regulator'' of T17 cell development, IL-23 inhibition is currently in process using antibodies that target its unique p19 subunit (eg, tildrakizumab, guselkumab, and risankizumab). Early clinical trials have demonstrated that sufficient inhibition of IL-23p19 results in rapid resolution of the clinical and histologic features associated with psoriasis similar (or even better) to that seen with IL-17 blockade. 73 In 2 early clinical studies relatively long-term treatment responses were observed in some patients with just a single doses of IL-23p19 inhibition 73, 74 ; this dramatic clinical response can be explained in part by promoting transdifferentiation of T H 17 cells into regulatory T cell or T H 1 populations. 75, 76 Phase III clinical trials evaluating the efficacy of tildrakizumab, guselkumab, and risankizumab for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis are ongoing.
Two Phase III clinical trials (VOYAGE 1 and 2) for the treatment of moderate-to-severe plaque psoriasis with guselkumab were recently published. 77, 78 Both VOYAGE trials were 48-week studies that compared guselkumab with placebo and adalimumab, although the VOYAGE 2 trial also evaluated the clinical response in patients with psoriasis with interrupted treatment (randomized withdrawal and retreatment). Results from the VOYAGE 1 and 2 trials were highly similar and reported a PASI90 response in 73% and 70% of patients at week 16, respectively, compared with approximately 50% of patients treated with adalimumab. More than one third of patients treated with guselkumab achieved a PASI100 response by week 16 compared with only about 15% of patients treated with adalimumab. Importantly, a separate phase III study (NAVIGATE trial) performed a head-to-head comparison of guselkumab and ustekinumab, which targets the p40 subunit of both IL-12 and IL-23. In this trial 51% and 20% of patients treated with guselkumab achieved a PASI90 and PASI100 response, respectively, whereas only 24% and 8% of patients in the ustekinumab treatment arm achieved a PASI90 and PASI100 response, respectively. 79 A recent phase II clinical trial further demonstrated the clinical superiority of selective p19 inhibition with risankizumab compared with inhibition of the shared p40 subunit by ustekinumab. 80 The most common adverse events reported in phase III trials with guselkumab were nonserious infections (eg, upper respiratory tract infections), nasopharyngitis, headache, arthralgias, and mild injection-site reactions. Rare adverse events included skin or soft-tissues abscesses and nonmelanoma skin cancers. Although the presence of anti-guselkumab antibodies were detected in approximately 5% of treated patients, no correlation was observed between antibody titer levels and loss of drug efficacy. Additional studies are necessary to better define the long-term efficacy and safety profiles of this class of biologics for the treatment of plaque psoriasis and psoriatic arthritis.
CONCLUSIONS AND FUTURE DIRECTIONS
The success of the IL-17 and IL-23 antagonists for the treatment of psoriatic disease has resulted in a modification of the primary clinical outcome being used in clinical trials. The treatment target has been moving to increased clearing of disease, such that PASI90 and PASI100 responses are now considered better targets than the PASI75 response. Still, the mere existence of patients with psoriasis whose symptoms do not improve with IL-17 or IL-23 blockade highlights the complexity of this chronic inflammatory skin condition. Differences in expression of specific IL-17 isoforms in various tissues, 81, 82 the synergistic effects of IL-17 with TNF, 46 or both might account for the lack of response in patients with recalcitrant disease. Therefore inhibition of more than 1 cytokine might be required to achieve disease resolution in essentially all patients. For example, with synergy of TNF and IL-17 for many inflammatory genes, dual inhibition of these cytokines (eg, a bispecific antibody) has been suggested; other bispecific antibodies target IL-17A and IL-17F combined. 83 However, the compounding of adverse effects and/or the high cost associated with this combination treatment strategy might limit its implementation in traditional clinical settings.
Many patients prefer oral medications over biologics that must be administered by means of injection. Currently approved drugs, such as methotrexate, cyclosporine, and apremilast, are used to treat psoriasis, but these drugs either have overall efficacies that are much lower than those of biologics (eg, apremilast induces PASI75 responses in about one third of patients with moderate-to-severe disease) 84 or there is poor tolerability or risk of organ dysfunction with long-term use. Newer small-molecule drugs currently in development are now based on targeting molecules that are more directly related to the IL-23/T17 T-cell axis, and thus these drugs might be able to improve on the efficacy and safety limitations of existing, less-selective small-molecular drugs. The development and testing of small-molecule inhibitors, such as Janus kinase enzyme and retinoic acid receptor-related orphan receptor gt (RORgt) inhibitors, offer another treatment modality with several advantages over traditional biologic medications. First, small molecules can be administered orally and can be potent inhibitors of specific immune populations, such as the T17 subset. 85 Second, they are synthetically manufactured and are relatively inexpensive compared with traditional biologic agents. Lastly, these synthetic small molecules access intracellular targets and lack the immunogenic properties associated with fully human or humanized antibodies. However, their inhibition of intracellular enzymes also accounts for their primary disadvantage (ie, unintended or off-target effects and/or the difficulty in predicting their biological effects). Several small-molecule inhibitors are currently undergoing clinical testing for the treatment of moderate-to-severe psoriasis, and it will be interesting to see how these agents compare in head-to-head trials against newer and highly effective mAbs.
In conclusion, our understanding of the immunologic, genetic, and autoimmune characteristics of psoriasis has improved substantially in the last decade. Insights into the importance of the IL-23/T17 signaling pathway have directly led to the development of some of the most effective treatments of psoriasis to date. The translational revolution we are witnessing raises the possibility of novel therapeutic strategies. Emerging bispecific antibodies offer the potential for improved disease control, while small-molecule drugs might offer future alternatives to the use of biologics and less costly long-term disease management.
Key concepts
d The cause of psoriasis is a complex interplay between the immune system, psoriasis-associated susceptibility loci, autoantigens, and multiple environmental factors.
d The IL-23/T17 axis represents the central immune pathway driving the development of psoriasis through the downstream effects of increased IL-17 levels.
d In response to IL-23, pathogenic T17 cells produce high levels of IL-17, which has broad inflammatory effects on keratinocytes and a variety of immune cells found in the skin.
d Increased levels of IL-17 produce a feed forward inflammatory response in keratinocytes that is self-amplifying and drives the development of mature psoriatic plaques by inducing epidermal hyperplasia, epidermal cell proliferation, and recruitment of leukocyte subsets into the skin.
d The high efficacy and good safety profile of novel mAbs against IL-17 and IL-23 underscore the central role of these cytokines as predominant drivers of psoriasis.
d Emerging bispecific antibodies offer the potential for improved disease control, whereas small-molecule drugs might offer future alternatives to the use of biologics and less costly long-term disease management.
